Skip to main
VCYT
VCYT logo

Veracyte (VCYT) Stock Forecast & Price Target

Veracyte (VCYT) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 40%
Buy 47%
Hold 7%
Sell 7%
Strong Sell 0%

Bulls say

Veracyte Inc. demonstrated a robust performance, with genomic test volume increasing by 25% to 39,107, driven largely by a remarkable 45% growth in Decipher urology tests, reflecting strong market demand. The company also achieved a significant increase in adjusted EBITDA margin, up 690 basis points year-over-year, highlighting improved operational efficiency and profitability. Furthermore, the impressive growth in revenue from Bethesda V and VI nodules following the July 2024 LCD for Afirma, along with management's optimistic guidance for adjusted EBITDA margins in 2025, underscores a positive outlook for the company moving forward.

Bears say

Veracyte Inc. faces a negative outlook primarily due to a slowdown in revenue growth, which declined from 29% in 3Q24 to 21% in 4Q24, driven by underperformance in key products like Afirma and Decipher tests. Additionally, testing revenue per test has decreased slightly, indicating potential pricing pressure, while a bear case scenario anticipates continued challenges with sustained revenue growth of only 10-15%. The company also faces significant risks including slower adoption of new diagnostic tests, reimbursement issues, and potential setbacks related to its Percepta Nasal Swab test, all of which could adversely impact its financial stability moving forward.

Veracyte (VCYT) has been analyzed by 15 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 47% recommend Buy, 7% suggest Holding, 7% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Veracyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Veracyte (VCYT) Forecast

Analysts have given Veracyte (VCYT) a Buy based on their latest research and market trends.

According to 15 analysts, Veracyte (VCYT) has a Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $36.53, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $36.53, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Veracyte (VCYT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.